Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
Argatroban is a selective thrombin inhibitor, and previous study had suggested that
argatroban use post PCI could potentially prevent reocclusion. But there has no study on
large sample of argatroban treated restenosis post cranial stenting. This study will test the
safety and efficacy of the argatroban on prevent occlusion and restenosis in patients with
intracranial and extracranial artery stenting.